Topoisomerase Inhibitors - Pipeline Insight, 2022
This report can be delivered to the clients within 3-4 working days
DelveInsight’s, “Topoisomerase Inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 60+ companies and 70+ pipeline drugs in Topoisomerase Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Topoisomerase Inhibitors: Overview
The topoisomerase enzymes play an important role in DNA metabolism, and searching for enzyme Inhibitors is an important target in the search for new anticancer drugs. Discovery of new anticancer chemotherapeutical capable of inhibiting topoisomerase enzymes is highlighted in anticancer research. Therefore, biologists, organic chemists and medicinal chemists all around the world have been identifying, designing, synthesizing and evaluating a variety of novel bioactive molecules targeting topoisomerase. Development of new anti-topoisomerase drugs, e.g. may allow to limit the cardiotoxic effect of anthracyclines or reduce the incidence of drug-induced secondary cancers. After all, the growing importance and rapid development of molecular genetics and molecular biology may enable the use of anti-topoisomerase agents in personalised anticancer therapy.
'Topoisomerase Inhibitors - Pipeline Insight, 2022' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Topoisomerase Inhibitors pipeline landscape is provided which includes the disease overview and Topoisomerase Inhibitors treatment guidelines. The assessment part of the report embraces, in depth Topoisomerase Inhibitors commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Topoisomerase Inhibitors collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Topoisomerase Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Topoisomerase Inhibitors Emerging Drugs
Further product details are provided in the report……..
Topoisomerase Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Topoisomerase Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
Topoisomerase Inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Topoisomerase Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Topoisomerase Inhibitors drugs.
Topoisomerase Inhibitors Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Topoisomerase Inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 60+ companies and 70+ pipeline drugs in Topoisomerase Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Topoisomerase Inhibitors: Overview
The topoisomerase enzymes play an important role in DNA metabolism, and searching for enzyme Inhibitors is an important target in the search for new anticancer drugs. Discovery of new anticancer chemotherapeutical capable of inhibiting topoisomerase enzymes is highlighted in anticancer research. Therefore, biologists, organic chemists and medicinal chemists all around the world have been identifying, designing, synthesizing and evaluating a variety of novel bioactive molecules targeting topoisomerase. Development of new anti-topoisomerase drugs, e.g. may allow to limit the cardiotoxic effect of anthracyclines or reduce the incidence of drug-induced secondary cancers. After all, the growing importance and rapid development of molecular genetics and molecular biology may enable the use of anti-topoisomerase agents in personalised anticancer therapy.
'Topoisomerase Inhibitors - Pipeline Insight, 2022' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Topoisomerase Inhibitors pipeline landscape is provided which includes the disease overview and Topoisomerase Inhibitors treatment guidelines. The assessment part of the report embraces, in depth Topoisomerase Inhibitors commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Topoisomerase Inhibitors collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Topoisomerase Inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve Topoisomerase Inhibitors.
This segment of the Topoisomerase Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Topoisomerase Inhibitors Emerging Drugs
- Datopotamab deruxtecan - Daiichi Sankyo
- Aldoxorubicin: ImmunityBio
Further product details are provided in the report……..
Topoisomerase Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Topoisomerase Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Topoisomerase Inhibitors
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Topoisomerase Inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Topoisomerase Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Topoisomerase Inhibitors drugs.
Topoisomerase Inhibitors Report Insights
- Topoisomerase Inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Topoisomerase Inhibitors drugs?
- How many Topoisomerase Inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Topoisomerase Inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Topoisomerase Inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Topoisomerase Inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
- Daiichi Sankyo
- ImmunityBio
- Monopar Therapeutics
- Luye Pharma
- Avacta
- Tarveda Therapeutics
- Cebiotex
- Cybrexa
- Datopotamab deruxtecan
- Aldoxorubicin
- Trastuzumab deruxtecan
- Camsirubicin
- LY 01610
- AVA6000
- PEN-866
- CEB-01
- CBX-12
Introduction
Executive Summary
Topoisomerase Inhibitors: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Datopotamab deruxtecan - Daiichi Sankyo
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
LY 01610: Luye Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early stage products (Phase I)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical stage products
Comparative Analysis
ELU-001: Elucida Oncology
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Topoisomerase Inhibitors Key Companies
Topoisomerase Inhibitors Key Products
Topoisomerase Inhibitors- Unmet Needs
Topoisomerase Inhibitors- Market Drivers and Barriers
Topoisomerase Inhibitors- Future Perspectives and Conclusion
Topoisomerase Inhibitors Analyst Views
Topoisomerase Inhibitors Key Companies
Appendix
Executive Summary
Topoisomerase Inhibitors: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Datopotamab deruxtecan - Daiichi Sankyo
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
LY 01610: Luye Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early stage products (Phase I)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical stage products
Comparative Analysis
ELU-001: Elucida Oncology
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Topoisomerase Inhibitors Key Companies
Topoisomerase Inhibitors Key Products
Topoisomerase Inhibitors- Unmet Needs
Topoisomerase Inhibitors- Market Drivers and Barriers
Topoisomerase Inhibitors- Future Perspectives and Conclusion
Topoisomerase Inhibitors Analyst Views
Topoisomerase Inhibitors Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Topoisomerase Inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Topoisomerase Inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Topoisomerase Inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Topoisomerase Inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
